经皮MR引导全腺体前列腺癌冷冻消融:30例连续患者的安全性考量与肿瘤学结果
研究回顾性分析2009年7月至2018年1月30例组织学证实的器官局限(≤T2cN0M0)、以低/中危为主的前列腺癌患者,接受MR引导全腺体冷冻消融,评估并发症、局部无进展生存和总生存;结论认为肿瘤学疗效好,尤其放疗后病例,并发症发生率虽高但多为轻微并可保守或药物治疗。
要点
- 30例患者中18例(60%)出现手术相关并发症,其中5/18(28%)需手术/介入治疗,13/18(72%)保守或药物治疗。
- 局部无进展生存率1年92.0%、3年75.7%、5年69.4%,总生存率1年100%、3年94.4%、5年88.5%。
- 挽救性治疗患者局部无进展生存率1年100%、3年75%、5年75%,无患者死于前列腺癌。
核心结论
- 全腺体前列腺癌冷冻消融提供良好的肿瘤学疗效,尤其在放疗后病例;并发症发生率显著但多数轻微,经保守或药物治疗管理。
研究设计与样本
- 回顾性研究,纳入2009年7月至2018年1月30例连续患者(平均年龄72.9±5.13岁),组织学证实为器官局限(≤T2cN0M0)、以低/中危为主的前列腺癌(中位Gleason评分7;平均PSA 6.05±3.74 ng/ml),接受MR引导全腺体冷冻消融;患者选择基于既往盆腔放疗(n=16;其中12例为既往前列腺癌)或手术/放疗禁忌/拒绝;回顾性调查并发症、局部无进展生存和总生存。
诊断标准与关键数值
- 局部无进展生存率:1年92.0%、3年75.7%、5年69.4%;挽救性治疗患者1年100%、3年75%、5年75%;总生存率:1年100%、3年94.4%、5年88.5%;平均PSA最低值0.24±1.5 ng/ml(平均随访3.8年,范围2-2915天);7例(23%)组织学证实局部进展(平均复发时间775天,范围172-2014天)。
临床应用与阅片要点
- 作者认为全腺体前列腺癌冷冻消融提供良好的肿瘤学疗效,尤其在放疗后病例,并发症发生率显著但多数轻微并经保守或药物治疗管理。
局限性
- 原文为回顾性研究。
- 原文未报告样本量小、单中心等局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the safety and oncological efficacy of percutaneous MR-guided whole-gland prostate cancer (PCa) cryoablation (CA).
METHODS AND MATERIALS: Between July 2009 and January 2018, 30 patients (mean age 72.9 ± 5.13 years) with histologically proven, organ-confined (≤ T2cN0M0), predominantly low/intermediate-risk PCa (median Gleason score 7; mean prostate specific antigen 6.05 ± 3.74 ng ml-1 ) underwent MR-guided whole-gland CA. Patients were selected on the basis of prior pelvic radiotherapy (n = 16; 12 for previous PCa), or contra indication/refusal of surgery or radiotherapy. Complications, local progression-free survival (LPFS) and overall survival (OS) were retrospectively investigated.
RESULTS: Eighteen [60%] patients reported procedure-related complications: 5/18 [28%] needed surgical/interventional treatments and 13 [72%] conservative or pharmacological treatment. Eleven [73%] complications were noted in the first 15 patients and 7 [47%] in the last 15 patients (p = 0.26). Mean nadir prostate specific antigen was 0.24 ± 1.5 ng ml-1 (mean follow-up 3.8 years; range: 2 - 2915 days). Seven [23%] patients developed histologically proven local progression (mean time to recurrence 775 days, range: 172 - 2014). Mean clinical follow-up was 3.8 years (range 1-2915 days). LPFS was 92.0, 75.7 and 69.4 % at 1-, 3- and 5 year follow-up, respectively. For patients in salvage treatment, LPFS was 100%, 75%, and 75% at 1-, 3- and 5 year follow-up. OS was 100%, 94.4 and 88.5 % at 1-, 3- and 5 year follow-up respectively, with no patients dying from PCa.
CONCLUSION: Whole-gland PCa CA offers good oncological efficacy, particularly in post-radiotherapy cases. Although the complication rate is significant, the majority is minor and is managed with conservative or pharmacologic management.
ADVANCES IN KNOWLEDGE: MRI-guided whole-gland prostate cancer cryoablation offers good oncological efficacy, particularly in post-radiotherapy cases with a contained complication rate.
引用
- De Marini P, Cazzato RL, Garnon J, et al. Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients. Br J Radiol. 2019. PMID: 30845821. doi:10.1259/bjr.20180965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。